Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MIL62
i
Other names:
MIL62, MIL 62, MIL-62
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Beijing Mabworks Biotech
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (174)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
mosunetuzumab-axgb (2)
rituximab-arrx (2)
IMM0306 (2)
IGM-2323 (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
ACTR087 (0)
ALETA-001 (0)
AcellBia (rituximab biosimilar) (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CM355 (0)
CMG1A46 (0)
DI Leu16 IL-2 (0)
(0)
GB241 (rituximab biosimilar) (0)
GB261 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
ocrelizumab (0)
PRO131921 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
IGN002 (0)
AME-133v (0)
XmAb13676 (0)
TG20 (rituximab biosimilar) (0)
rituximab (174)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
mosunetuzumab-axgb (2)
rituximab-arrx (2)
IMM0306 (2)
IGM-2323 (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
ACTR087 (0)
ALETA-001 (0)
AcellBia (rituximab biosimilar) (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CM355 (0)
CMG1A46 (0)
DI Leu16 IL-2 (0)
(0)
GB241 (rituximab biosimilar) (0)
GB261 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
ocrelizumab (0)
PRO131921 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
IGN002 (0)
AME-133v (0)
XmAb13676 (0)
TG20 (rituximab biosimilar) (0)
›
Associations
News
Trials
Filter by
Latest
1year
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: May 2023 --> May 2025 | Trial primary completion date: Jan 2023 --> May 2024
1 year ago
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
over1year
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2023 --> Mar 2024
over 1 year ago
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62
2years
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=43, Active, not recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Active, not recruiting | N=120 --> 43
2 years ago
Enrollment closed • Enrollment change
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Yinuokai (orelabrutinib) • MIL62
2years
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Jun 2022 --> Jan 2023
2 years ago
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
over2years
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62
over3years
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=120, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Not yet recruiting --> Recruiting | N=50 --> 120 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2025
over 3 years ago
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Yinuokai (orelabrutinib) • MIL62
over3years
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
over 3 years ago
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
lenalidomide • MIL62
over3years
A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas (clinicaltrials.gov)
P1, N=27, Completed, Beijing Mabworks Biotech Co., Ltd. | Active, not recruiting --> Completed
over 3 years ago
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
MIL62
over3years
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=168, Not yet recruiting, Beijing Mabworks Biotech Co., Ltd.
over 3 years ago
New P3 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • MIL62
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login